Skip to content
value.today

Elucida Oncology, Inc.

🇺🇸 New York, New York, USABiotechnologyFounded 2014
Total raised
$95 M
4 rounds on record
Latest round
$22 M
May 2023
First round on record
Aug 2017
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Elucida Oncology, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2023$22 MNo. 4$10 to $50 million

Elucida Oncology, Inc.: Raise no. 4, May 2023

Investors in this round

107 investors had bought by the notice of Aug 3, 2023: 107 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$22 M of $22 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$2,228,460
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Geno Germano · Executive Officer, Director
  • Robert Essner · Executive Officer, Director
  • David Zacardelli · Director
  • Gary Sender · Director
  • Natalie MacDonald · Director
  • Robert Ruffolo · Director
  • Tim Boris · Director
  • Ulrich Wiesner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 120708) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “In addition, the Company issued the Placement Agent Warrants to purchase 526,316 shares of Common Stock of Elucida in connection with the offering.”

Signed by Geno Germano, Ceo. Newest notice filed Aug 3, 2023 (1 amendment). Read the notice at the SEC.

debt, optionsSEC
Oct 2020$35 MNo. 3$10 to $50 million

Elucida Oncology, Inc.: Raise no. 3, Oct 2020

Investors in this round

328 investors had bought by the notice of Jan 12, 2021: 328 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$35 M of $35 M offered
Smallest investment taken
$12,500
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$3,500,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eliel Bayever · Executive Officer
  • Geno Germano · Executive Officer, Director
  • Gregory Adams · Executive Officer
  • Kai Ma · Executive Officer
  • Robert Essner · Executive Officer, Director
  • Michael Smith · Director
  • Robert Ruffolo · Director
  • Teresa Ressel · Director
  • Tim Boris · Director
  • Ulrich Wiesner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 12078) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “In addition, the Company issued the placement agent Warrants to purchase 4,605,246 shares of common stock of Elucida in connection with the offering.”

Signed by Geno Germano, Ceo. Newest notice filed Jan 12, 2021 (3 amendments). Read the notice at the SEC.

equitySEC
May 2020$9 MNo. 2$2 to $10 million

Elucida Oncology, Inc.: Raise no. 2, May 2020

Investors in this round

126 investors had bought by the notice of Jun 4, 2020: 126 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $30 M offered; $21 M still to sell
Smallest investment taken
$11,400
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$774,072
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Geno Germano · Executive Officer, Director
  • Robert Essner · Executive Officer, Director
  • Michael Smith · Director
  • Robert Ruffolo · Director
  • Teresa Ressel · Director
  • Tim Boris · Director
  • Ulrich Wiesner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 12078) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “In addition, the Company issued the placement agent Warrants to purchase 1,150,096 shares of common stock of Elucida in connection with the offering.”

Signed by Geno Germano, Ceo. Newest notice filed Jun 4, 2020 (1 amendment). Read the notice at the SEC.

equitySEC
Aug 2017$29 MNo. 1$10 to $50 million

Elucida Oncology, Inc.: Raise no. 1, Aug 2017

Investors in this round

175 investors had bought by the notice of Feb 7, 2019: 175 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$29 M of $30 M offered; $1 M still to sell
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$2,875,960
Finders' fees
none
Paid to its own people
$400,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Geno Germano · Executive Officer, Director · Chief Executive Officer
  • Isaac Blech · Director
  • Michael T. Smith · Director
  • Robert A. Essner · Director
  • Robert A. Ruffolo · Director
  • Teresa M. Ressel · Director
  • Tim Boris · Director
  • Ulrich T. Wiesner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 12078) · New York, New YorkSold in all US states

Remarks in the notice

  • On the use of proceeds: “Upon a closing of $15 million in the aggregate, Mr. Edward Rosen, the Company's former CEO, is entitled to the receive up to $400,000 relating to various consulting fees and the reimbursement of expenses pursuant to the terms of his employment agreement.”

Signed by Geno Germano, Chief Executive Officer. Newest notice filed Feb 7, 2019 (2 amendments). Read the notice at the SEC.

equity, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Elucida Oncology, Inc. had no revenue when it filed its newest notice of a funding round (Aug 2023).

    SEC Form D (revenue range) · Aug 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2023

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Elucida Oncology, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Elucida Oncology, Inc.
NameRoleNamed in
Geno GermanoExecutive officerAug 2023
Robert EssnerExecutive officerAug 2023
Eliel BayeverExecutive officerJan 2021
Gregory AdamsExecutive officerJan 2021
Kai MaExecutive officerJan 2021
Edward RosenChief Executive OfficerAug 2017
David ZacardelliDirectorAug 2023
Gary SenderDirectorAug 2023
Geno GermanoDirectorAug 2023
Natalie MacDonaldDirectorAug 2023
Robert EssnerDirectorAug 2023
Robert RuffoloDirectorAug 2023
Tim BorisDirectorAug 2023
Ulrich WiesnerDirectorAug 2023
Michael SmithDirectorJan 2021
Teresa ResselDirectorJan 2021
Isaac BlechDirectorFeb 2019
Michael T. SmithDirectorFeb 2019
Robert A. EssnerDirectorFeb 2019
Robert A. RuffoloDirectorFeb 2019
Teresa M. ResselDirectorFeb 2019
Ulrich T. WiesnerDirectorFeb 2019
Edward RosenChief Executive OfficerAug 2017
Isaac A. BlechDirectorAug 2017
Michelle A. BradburyDirectorAug 2017
Sigurdur A. OlafssonDirectorAug 2017
Steven LarsonDirectorAug 2017
Tim A. BorisDirectorAug 2017